anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of tebipenem, followed by sampling of interstitial tissue fluid by a microdialysis probe inserted in a thigh over 8 hours following the last dose.
The present invention provides a pharmaceutical composition containing carfilzomib and a preparation method thereof. The pharmaceutical composition comprises carfilzomib as an active ingredient, protein and pH regulator. The pH value ranges from 2 to 5, the average particle size is less than 200nm, the Zeta potential is -20 to -30mV, and the mass ratio of carfilzomib to protein is 1:6-12. The invention aims to provide the pharmaceutical composition containing carfilzomib which is better used for the in-vivo delivery of carfilzomib, the pharmaceutical composition does not contain the sulfobutylether-beta-cyclodextrin in currently listed carfilzomib injection, so as to avoid the occurrence of allergic reactions and prevent vasospasm and phlebitis caused by the clinical use of the pharmaceutical composition. The freeze-dried preparation of pharmaceutical composition can be prepared by high-pressure homogenization, and can be transformed into blocks or powder which can re-disperse. After re-dispersing in an aqueous medium, compared with the products in current market, the stability of the pharmaceutical composition is increased significantly, and the safety of medication in clinical application is enhanced.
Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void ("retrograde-fill" technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL.
OBJECTIVES: The study aimed to investigate the interaction of intraoperative stress hyperglycemia with monocyte functions and their impact on major adverse events (MAEs) in acute aortic dissection (AAD) patients who underwent open repair surgery.
METHODS: A total of 321 adults who underwent open surgery for AAD at two tertiary medical centers in China were enrolled in the study. The primary endpoint was defined as the incidence and characteristics of perioperative stress hyperglycemia. The secondary endpoints included the incidence of postoperative MAEs, postoperative monocyte counts and inflammatory cytokine expression. Multi-logistic, linear regression and receiver operating characteristic (ROC) curve analyses were used to establish relationships between intraoperative time-weighted average glucose (TWAG), day-one postoperative monocyte counts, serum inflammatory cytokines and postoperative outcomes. In addition, in vitro experiments were conducted to evaluate changes in the inflammatory features of monocytes under high glucose conditions.
RESULTS: Intraoperative hyperglycemia, as indicated by a TWAG level over 142 mg/dL, was associated with elevated postoperative monocyte counts and inflammatory cytokines, which correlated with extended intensive care unit (ICU) stays and worsened outcomes. In vitro, high glucose treatment induced mitochondrial impairment in monocytes, increased the release of inflammatory cytokines and the proportion of classical monocytes from AAD patients.
CONCLUSIONS: Intraoperative stress hyperglycemia, in combination with day-one postoperative monocyte counts, were clinically significant for predicting adverse outcomes in AAD patients undergoing open repair surgery. Elevated glucose concentrations shaped the inflammatory features of monocytes in AAD by impairing mitochondrial functions.
PURPOSE: CTLA4 deficiency is an inborn error of immunity (IEI) due to heterozygosity for germline loss-of-function variants of the CTLA4 gene located on chromosome 2q33.2. CTLA4 deficiency underlies pleiotropic immune and lymphoproliferation-mediated features with incomplete penetrance. It has been identified in hundreds of patients but copy number variants (CNVs) have been reported in only 12 kindreds, including nine which displayed large 2q33.1-2q33.2 deletions encompassing CTLA4.
METHODS: We conducted a nationwide study in France to identify patients with 2q33 deletions encompassing CTLA4. We investigated the clinical and immunological phenotypes and genotypes of these patients.
RESULTS: We identified 12 patients across six unrelated kindreds with clinical immunodeficiency. Neurological features were recorded in three patients, including one with syndromic neurodevelopmental disorder. Single-nucleotide polymorphism (SNP) or comparative genomic hybridization (CGH) array analysis, and targeted high-throughput sequencing revealed five different heterozygous 2q33 deletions of 26 kilobases to 7.12 megabases in size and encompassing one to 41 genes. We identified a contiguous gene syndrome (CGS) due to associated KLF7 deficiency in a kindred with a neurodevelopmental phenotype.
CONCLUSION: Deletions within the 2q33 region encompassing CTLA4 are rare and not extensively explored, and are probably underdiagnosed in cytogenetic practice. A literature review identified 14 different CGS loci including at least one gene responsible for an IEI. The deletions involved in IEIs should be systematically delimited, to facilitate screening for CGS.
An interactive multimedia computer-based treatment program was developed to provide an electronic version of problem solving therapy for depression (imbPST). The program was entirely automated and did not require the involvement of a live clinician, even though it was designed to provide a "virtual therapy" experience that feels more like interacting with a person than with a computer. The imbPST program was built to help individuals who did not have access to traditional therapy due the living conditions or individual preferences (e.g. rural, poor and persons desiring privacy or with significant time constraints). This computer-based treatment of depression offered several advantages. It can be used anywhere without a therapist present, and offered a standardized and consistent therapeutic approach.

The aim of this study is to reduce symptoms of depression in subjects through the use of a new, electronic Problem Solving Treatment (imbPST). Adult participants with moderate to severe depression symptoms are randomly assigned to either treatment or a wait-list condition. The Beck Depression Inventory-II was used as the primary outcome measure
The study will examine whether a stress reduction intervention reduces the number of seizures in people with drug resistant epilepsy. In the proposed randomized controlled, double blind trial, the investigators will enroll subjects with frequent seizures, especially those who identify stress as a seizure precipitant. There is an observational phase (8-12 weeks) and a treatment phase (12 weeks). During the observational phase, subjects will be monitored multiple times daily via smart phone devices, in order to identify high risk days for seizures. In the treatment phase, subjects will be randomly assigned to one of two groups receiving different focused attention practices. These behavioral interventions will be administered daily with extra interventions applied on days of higher risk.
BACKGROUND: Androgenetic alopecia (AGA) causes thinning hair, but poor hair quality in balding areas and damage from UV radiation have been overlooked. Plant extracts like Platycladus orientalis flavonoids (POFs) may improve hair quality in AGA. This study examines POFs' effectiveness in treating AGA-affected hair and repairing UV-induced damage.
METHODS: Hair samples were analyzed using scanning electron microscopy (SEM) to examine surface characteristics, electron paramagnetic resonance (EPR) spectroscopy to measure free radicals in the hair, and spectrophotometry to assess changes in hair properties.
RESULTS: POFs effectively removed hydroxyl radicals from keratinocytes and had antioxidant properties. They also reduced UV-induced damage to AGA hair by mitigating the production of melanin free radicals. Following POF treatment, the reduction in peroxidized lipid loss in AGA hair was notable at 59.72%, thereby effectively delaying the progression of hair color change. Moreover, protein loss decreased by 191.1 μ/g and tryptophan loss by 15.03%, ultimately enhancing hair's tensile strength.
CONCLUSION: compared to healthy hair, hair damaged by AGA shows more pronounced signs of damage when exposed to UV radiation. POFs help protect balding hair by reducing oxidative damage and slowing down melanin degradation.
A personal care composition may have an isosorbide diester having the formula (I): wherein R' and R" are independently selected from a straight or branched C 1-30  chain, which may be saturated or unsaturated. The composition may further comprise a solid UV active soluble in the isosorbide diester and a dermatologically acceptable carrier. The personal care composition may be in the form of an emulsion having an aqueous phase comprising water and an oil phase. The oil phase may comprise the isosorbide diester and a solid UV active soluble in the isosorbide diester. In a particular embodiment, the solid UV soluble in the isosorbide diester UV active may be selected from 4-tert-butyl-4'-methoxy dibenzoylmethane, bis-ethylhexyloxyphenol methoxyphenyl triazine, and combinations thereof. Methods of making the aforementioned personal care compositions are disclosed.
This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
The experimental group will receive 40 minutes of MT, followed by 40 minutes of AR training and 10 minutes of functional practice. Figure 2 provides an illustration of the hybrid regimen of MT+AR.
Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20-30 minutes.

The penicillinase-resistant penicillins bind to serum protein, mainly albumin. The degree of protein binding reported for oxacillin is 94.2% ± 2.1%. Reported values vary with the method of study and the investigator.

The penicillinase-resistant penicillins vary in the extent to which they are distributed in the body fluids. With normal doses, insignificant concentrations are found in the cerebrospinal fluid and aqueous humor. All the drugs in this class are found in therapeutic concentrations in the pleural, bile, and amniotic fluids.

The penicillinase-resistant penicillins are rapidly excreted primarily as unchanged drug in the urine by glomerular filtration and active tubular secretion. The elimination half-life for oxacillin is about 0.5 hours. Nonrenal elimination includes hepatic inactivation and excretion in bile.

Probenecid blocks the renal tubular secretion of penicillins. Therefore, the concurrent administration of probenecid prolongs the elimination of oxacillin and, consequently, increases the serum concentration.
PROBLEM TO BE SOLVED: To provide an aqueous composition for moisture retention, which can be used before work to contact with food such as cooking and has both high safety and moisture retention properties.SOLUTION: A aqueous composition for moisture retention comprises 50-200 pts.wt. of glycerin, 1-10 pts.wt. of water-soluble cellulose or a derivative thereof, 1-10 pts.wt. of water-soluble starch or a derivative thereof and 0.5-5 pts.wt. of polycarboxylic acid, relative to 100 pts.wt. of water.
Class I (20-30 mmHg) compression bandages or stocking. This is considered a standard measure in the recovery of lower extremity wounds and often recommended.
Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
Signs and Symptoms:Headache, irritability, nervousness, tremor, sweating, increased bowel motility and menstrual irregularities. Angina pectoris, arrhythmia, tachycardia, acute myocardial infarction or congestive heart failure may be induced or aggravated. Shock may also develop if there is untreated pituitary or adrenocortical failure. Massive overdosage may result in symptoms resembling thyroid storm. 

Treatment of Overdosage:Dosage should be reduced or therapy temporarily discontinued if signs and symptoms of overdosage appear. Treatment may be reinstituted at a lower dosage. In normal individuals, normal hypothalamic-pituitary- thyroid axis function is restored in six to eight weeks after cessation of therapy following thyroid suppression. 

Treatment is symptomatic and supportive. Oxygen may be administered and ventilation maintained. Cardiac glycosides may be indicated if congestive heart failure develops. Beta-adrenergic antagonists have been used advantageously in the treatment of increased sympathetic activity. Measures to control fever, hypoglycemia or fluid loss should be instituted if needed.
If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
Method of the transfer factor medicine preparation; transfer factor medicine; biological activity testing methodology; pharmaceutical form and its use where the Method of the medicine preparation from the peripheral blood leukocytes is based on the following individual steps, i.e. from: a) prepared leukocyte concentrate, b) dialysis and/or filtration, c) removal of salts and concentration with use of nanofiltration, d) thermal activation, e) tablet formulation and f) preparation of a lyophilised tablet, while the steps comprising removal of salts from the product and concentration of the product with use of nanofiltration are based on purifying the obtained dialysate of undesired salts and its concentration with use of nanofiltration to the required volume. A thin-film polyamide composite is used for concentration with use of nanofiltration as a membrane with the porosity allowing for permeability of up to 1,000 Da. The transfer factor active substance prepared as a Iyophilised tablet that is Iyophilised directly in the blister pocket where each pocket represents one dose of the preparation; the medicine is made of dialysate or ultrafiltrate of the peripheral blood leukocytes purified of ballast salts and comprising protein substances and nucleic acid substances whose ratio in the medicine, i.e., the absorption,index, is not under 1.7, where the molecular weight of none of the medicine substances is greater than 10,000 Daltons. The in vitro method of testing the biological activity of the transfer factor active substance is conducted through observing the transfer factor impact on the model cellular line viability after it was influenced by an immunosuppressive substance, azathioprine. Using of the transfer factor in the form of a Iyophilised tablet administered in the oral cavity where the Iyophilised tablet immediately adheres to the mucosa, which prevents its swallowing; it speedily melts on the buccal mucosa and it passes directly to the digestive system as a human or veterinary medicine or a food supplement or a prophylactic preparation.
While fatigue is seen with a prevalence of 7-8% in the normal population, it is more prevalent in Primary Sjögren's syndrome (PSS). In the studies conducted so far, the frequency of fatigue was seen at a frequency of over 30% in Primary Sjögren's syndrome. Although fatigue is so common in PSS, there is not enough data about the conditions in which fatigue develops in PSS. Other common conditions in PSS, apart from fatigue, are psychometric disorders such as common pain, depression and anxiety, and sleep disorders. In the studies conducted so far, each situation mentioned is common in PSS and seems to be related to each other. In the literature, there is no data on how many psychometric parameters, pain level, and insomnia affect fatigue and which are independent risk factors in PSS.
This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln10I antibodies. Other aspects of the invention are a method of killing an Cln101-expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal.
Adipose tissue (AT), once considered a mere fat storage organ, is now recognized as a dynamic and complex entity crucial for regulating human physiology, including metabolic processes, energy balance, and immune responses. It comprises mainly two types: white adipose tissue (WAT) for energy storage and brown adipose tissue (BAT) for thermogenesis, with beige adipocytes demonstrating the plasticity of these cells. WAT, beyond lipid storage, is involved in various metabolic activities, notably lipogenesis and lipolysis, critical for maintaining energy homeostasis. It also functions as an endocrine organ, secreting adipokines that influence metabolic, inflammatory, and immune processes. However, dysfunction in WAT, especially related to obesity, leads to metabolic disturbances, including the inability to properly store excess lipids, resulting in ectopic fat deposition in organs like the liver, contributing to non-alcoholic fatty liver disease (NAFLD). This narrative review delves into the multifaceted roles of WAT, its composition, metabolic functions, and the pathophysiology of WAT dysfunction. It also explores diagnostic approaches for adipose-related disorders, emphasizing the importance of accurately assessing AT distribution and understanding the complex relationships between fat compartments and metabolic health. Furthermore, it discusses various therapeutic strategies, including innovative therapeutics like adipose-derived mesenchymal stem cells (ADMSCs)-based treatments and gene therapy, highlighting the potential of precision medicine in targeting obesity and its associated complications.
The embodiments herein provide a pharmaceutical composition for use in a combination with cannabinoids that includes a primary essential oil, and a secondary essential oil to support the human endocannabinoid system. The primary essential oil replenishes a plurality of first micronutrients lost during the processing of cannabis. The primary essential oil contains a first therapeutically effective amount of crude cannabis essential oil. The secondary essential oil replenishes a plurality of second micronutrients lost during the processing of cannabis. The secondary essential oil contains a second therapeutically effective amount of crude cannabis essential oil. The primary essential oil and the secondary essential oil are in a liquid form. The liquid form of the primary essential oil and the secondary essential oil are respectively transformed into a powder form by performing a microencapsulation process.
The invention belongs to a formula of an external medicine tincture and a production method thereof. The invention relates to a 010 anti-hair loss hair-growing liquid. The two medicines are prepared from multiple medicinal Chinese traditional medicines. The preparation method comprises the following steps: carrying out scientific screening on drugs, processing crude drugs, preparing and the like. The medicine is suitable for treating various alopecia, and can stimulate hair follicle tissues to regenerate. For early alopecia, the invention has obvious curative effect, and the total efficiency is 98.6%. The invention has the advantages of stable drug effect, no side effect, convenient use, long hold time and clinic practicality and pertinence. When being directly applied on the skin of a patient, the invention can promote hair to grow quickly. Thus, the invention is a conventional way for treating alopecia in hospitals in China, and is an excellent external medicine with especially good effect on hair regeneration.
PURPOSE: An oriental medicinal cosmetic product for treating acne and a method for manufacturing the same are provided to ensure persistence and safety without side effects and to relieve and treat acne. CONSTITUTION: An oriental medicinal cosmetic product for treating acne contains 0.3-10 weight% of oriental medicinal herb extract. The oriental medicinal herb extract includes 30-50 weight% of ginkgo leaf extract, 20-40 weight% of Perilla frutescens var. acuta extract, and 20-40 weight% of deer angler extract. The extract is isolated using water, ethanol. A method for manufacturing the oriental medicinal cosmetic product for treating acne comprises: a step of washing ginkgo leaves, Perilla frutescens var. acuta, and deer antler for removing foreign materials; a step of extracting the ginkgo leaves, Perilla frutescens var. acuta, and deer antler with distilled water or ethanol; a step of mixing the oriental medicinal herb extract; and a step of adding cosmetic ingredient with 0.3-10 weight% of medicinal herb extract.